Lifecore Biomedical EV/EBIT LFCR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 10.0×; Oct 2022
10-year median: 27.5×
10-year range: 10.0× to 128×
Peer median: 4.9×

Lifecore Biomedical's EV/EBIT is not a meaningful number today: no quarters with one-off gains and charges taken out yet.

It was last meaningful in Oct 2022, at 10.0×.

On the days it had one over the last ten years, its median was 27.5×, from 10.0× in Oct 2022 to 128× in Dec 2019.

EV/EBIT over time

median 27.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	10.0×	10.0×	86.3×
2021	90.2×	28.9×	103×
2020	n/m a value too high to mean anything
2019	127×	24.8×	128×
2018	27.6×	24.7×	43.0×
2017	19.3×	14.6×	23.4×
2016	25.0×	18.0×	27.2×
2015	18.8×	17.0×	24.1×
2014	19.1×	15.3×	22.6×
2013	14.9×	13.9×	23.3×
2012	18.7×	17.1×	22.2×

Against its peers

Companies in Drug Manufacturers - General nearest Lifecore Biomedical's size, closest first, today.

Company	EV/EBIT
LFCRLifecore Biomedical	n/m
NATRNatures Sunshine Products	5.2×
ARVNArvinas	n/m
PBYIPuma Biotechnology	15.6×
IRWDIronwood Pharmaceuticals	3.5×
ZVRAZevra Therapeutics	2.9×
CRMDCorMedix	2.3×
COLLCollegium Pharmaceutical	9.4×
LFVNLifevantage	9.6×
ABUSArbutus Biopharma	4.9×
SPROSpero Therapeutics	2.1×
Peer median	4.9×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Lifecore Biomedical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.